Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00427414 · ClinicalTrials.gov registry record · Phase 1
Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma
A Phase 1 study, sponsored by AIDS Malignancy Consortium.
- Terminated
- Registry status
- Phase 1
- Development phase
- 14
- Enrollment target
NCT00427414: Clinical Trial Phase 1 study, sponsored by AIDS Malignancy Consortium.
NCT00427414 is a Phase 1 study that was terminated before completion, run by AIDS Malignancy Consortium. The registered enrollment target is 14 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00427414, a Phase 1 study, was terminated before completion, sponsored by AIDS Malignancy Consortium.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
RATIONALE: Drugs used in chemotherapy, such as liposomal daunorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This clinical trial is studying how well liposomal daunorubicin works in treating patients with HIV-related Kaposi's sarcoma.
Interventions
- DRUG liposomal daunorubicin citrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2008-09 |
| Est. Completion | 2011-11 |
| Phase | Phase 1 |
Why NCT00427414 stopped before completion
NCT00427414 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 1 intervention - of which liposomal daunorubicin citrate is the first listed.
NCT00427414 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00427414 about?
NCT00427414 is a clinical study titled "Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma". RATIONALE: Drugs used in chemotherapy, such as liposomal daunorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This clinical trial is studying how well liposomal daunorubicin works in treating patients with HI...
What is the current status of trial NCT00427414?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 14 participants. The study started on 2008-09. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00427414?
The interventions under investigation include: liposomal daunorubicin citrate (DRUG).
Who is sponsoring clinical trial NCT00427414?
This trial is sponsored by AIDS Malignancy Consortium, which has 45 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00427414's enrollment target sits among peer trials
14 1844th of 2000 higher than 154 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia